Abstract
Introduction
Viral hepatitis is a major public health problem in developing and developed countries affecting millions of children every year despite the availability of vaccines, prophylactic measures and improved sanitation. Hepatitis A (HAV) and E (HEV) only cause acute hepatitis but hepatitis B virus (HBV) and C virus (HCV) are important cause of morbidity and mortality through chronic infections and are major causes of acute and chronic liver disease worldwide and often leads to cirrhosis or primary hepatocellular carcinoma. 1, 2 Hepatitis A virus (HAV) is the most common cause of acute viral hepatitis worldwide. 3 Globally it is responsible for at least 1.4 million new infections each year. 4 Although infection with HAV is often mild and asymptomatic in young children, the disease can be severe in adults. 5 The distribution and prevalence of HAV infection is very closely related to local hygiene and sanitation conditions, and consequently may vary across countries depending on the socioeconomic status (SES) of the population. 6 The highest incidence of hepatitis A infection has previously been reported in developing countries of Africa, Central and South America and South-East Asia. 7, 8 Bangladesh is considered to be a country where hepatitis A infection is hyperendemic with 100% of children ≤ 6 years of age exposed and immune to HAV. 5,9 However, rapid improvements in hygiene and socioeconomic conditions, specifically in sections of the urban population, are taking place.
Hepatitis E virus (HEV), an emerging pathogen, 10,11 causes significant disease in endemic countries and is the leading cause of enterically transmitted viral hepatitis illness globally. 12 Large annual epidemics are attributed to HEV, 12,13 and studies suggest that HEV is etiologically responsible for 10%-95% of admitted cases of hepatitis across South Asia. 14 Globally, prevalence rates of antibody to hepatitis E virus (anti-HEV) vary by region, population, and circulating genotypes of HEV, with unexpectedly high seropositivity in some developed settings. 14 The prevalence of HBV infection varies from country to country and within countries, having a close association with behavioral, environmental host factors. It has been estimated that there are approximately 350 million HBV carriers in the world, of whom 80% are Asians. 15 Over 90% of infants, 50% of children and 5% of adults with acute hepatitis B will develop chronic or long-term infection. The current prevalence of chronic hepatitis B (based on seropositivity for HBsAg) in Bangladesh ranges from 4.4% to 7.5%. However, among high-risk populations, the sero-prevalence of HBsAg is as high as 29%. 16 Other study shows about 7% -10% population have hepatitis B infection, and 3%-5% pregnant mothers The higher seropositivity of HEV infection among adults (56.1%) compared to children (34.78%) in our study is also similar to that of research work published on population based studies in India, Pakistan, Hong Kong and Somalia. [22] [23] [24] [25] Although hepatitis B vaccine is available for the last 25 years, still majority of the population of Bangladesh can not afford the vaccine due to various reasons. More over unsafe use of blood and blood products, sharing of needles and lack of proper knowledge regarding hepatitis B is prevailing in Bangladesh. This is well reflected by the high sero-positivity of HBsAg (8%) in this study. Hepatitis B virus vaccin is now included in the EPI and is being provided free of cost for the last few years but the reflection of vaccine coverage is not yet evident. Our sero-positivity is less than that of Pakistan 24 and Kenya 26 where the sero-positivity found is 10% and 26.2% respectively.
Study done by Malathi et al in India showed a 22 % prevalence of Hepatitis B among the children admitted in hospital for acute viral hepatitis. 24 In the present study HBsAg was positive in 8% cases. In this study only outdoor patients were taken as sample.
In this study, as found from the history of the patients, transfusion of blood and blood-products did not play any role in causing sero-positivity of hepatitis B viral markers. In this study, no case was detected positive for HCV. HCV prevalence is around 3% in most parts of the world. 27
In conclusion, the present study indicates high seropositivity of hepatotropic viruses like HAV (65.22%), HEV (34.78%) and HBV (8%) in patients suffering from acute hepatitis in Bangladesh. Urgent and strict preventive measures are needed to combat this menace. Further large scale studies with appropriate design & sample size are required in this regard.
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